A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mesna; Methotrexate; Vincristine
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2018 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 29 Nov 2017 Planned number of patients changed from 100 to 131.
- 13 Dec 2016 Planned number of patients changed from 50 to 100.